CoR Bio-Tech provides the world,
sickness is optional
CoR Bio-Tech: An Unprecedented Solution for Preventing and Repairing Aging
US Patent No: 11273135
CoR Bio-Tech has unveiled a revolutionary redox reaction within mitochondria involving the electron acceptor FAD. This breakthrough not only initiates metabolism to protect DNA, prevent protein cross-linking, and mitigate the release of free radicals but also ensures a continuous supply of vital energy currency for cellular structures and functions. With these dual functionalities, this innovation offers a transformative solution to combat human degeneration and opens up a wide array of promising potential applications.
Mitochondria
CoR Bio-Tech's pioneering approach not only aims to prevent but also effectively treat aging-related chronic diseases. This is particularly crucial as 89 genes encoding FAD have been pinpointed in the human genome. FAD plays a significant role in the folate and cobalamin metabolism, essential for the biosynthesis of coenzymes and hormones, linking a substantial portion of human diseases to FAD. Many FAD-related disorders in humans arise from mutations in these genes. As most flavoproteins are housed in mitochondria, deficiencies in mitochondrial processes are associated with these diseases. Furthermore, numerous genes encoding FAD manifest as allelic variants that have the potential to lead to severe human ailments. The spectrum of allelic variants ranges widely, from just a few to over a hundred.
Our Mission & Vision
CoR Bio-Tech offers innovative solutions that are revolutionizing the intellectual property landscape in drug discovery. Our committed team is actively engaged in the seamless integration of this pioneering technology with organizations seeking to collaborate, accelerate, partner, license, and integrate it into their continuous efforts in drug research and development.
CoR innovation provides the world where
sickness is optional now
LIHTI Stony Brook University
25 Health Science Drive
Stony Brook NY 11790
Cor4mito, Inc. All rights reserved.